Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

    Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal injection.

  • Panacea Biotech gets order of USD 127.30 million from UNICEF & PAHO for pentavalent vaccine

    Panacea Biotec, one of India's leading biotechnology companies, has received long-term supply awards worth USD 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT'" (DTwP-HepB-Hib).

  • Zinc could treat a rare genetic disorder

    Paediatric encephalopathies of genetic origin cause severe motor and intellectual disabilities from birth. One of these diseases, first identified in 2013, is caused by mutations in the GNAO1 gene. In order to understand the finer details of the resulting disturbances, scientists from the University of Geneva (UNIGE) conducted atomic, molecular and cellular analyses. They discovered that a mutation in GNAO1 leads to the replacement of one amino acid by another in protein sequence.

  • Celebrating 38th Foundation Day of IIHMR, Jaipur

    Indian Institute of Health Management Research (IIHMR) was established on 5 October 1984. To commemorate this special day IIHMR University celebrated its 38th Foundation Day on October 7, 2022.

    The event was graced by the benign presence of Chief Guest, Dr. Vishwa Mohan Katoch, President, JIPMER, Puducherry, Chairman, AIIMS, Madurai, Chairman LEPRA Society, Former Secretary, Department of Health Research, Government of India and Director General, Indian Council of Medical Research.

  • NPPA notified ceiling prices of cardiac stent remains same as earlier

    NPPA has received requests from few companies about trade margin clarification of cardiac stents. On which, NPPA notified that ceiling prices of cardiac stent remains same as earlier without any changes as notified on 30th March 2022 till further notice.

  • Detecting Alzheimer’s disease in the blood

    Researchers from Hokkaido University and Toppan have developed a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s disease, from biomarkers in blood samples.

  • Widespread dysregulation of metabolism in type 2 diabetes

    Using state of the art techniques, researchers from Uppsala University have shown that the metabolism in patients with type 2 diabetes and prediabetes was much more disturbed than previously known, and that it varied between organs and severity of the disease. The study is a collaboration with e.g. Copenhagen University and AstraZeneca and it has been published in the journal Cell Reports Medicine.

  • Pfizer Completes Acquisition of Global Blood Therapeutics

    Pfizer Inc announced the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease (SCD). The acquisition reinforces Pfizer’s commitment to SCD, building on a 30-year legacy in the rare hematology space.

  • Controversial syrup was only sent to Gambia, says Regulators

    It has come to notice that controversial syrups exported by India based Maiden Pharmaceutical are linked to the death of 66 children in Gambia. Regulators informed that the company has manufactured and exported these products only to Gambia.

  • Lilly receives U.S. FDA Fast Track designation for tirzepatide

    Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track designation is intended to bring promising medicines to patients sooner.

Subscribe to Pharma News